On October 13, the drug manufacturer Sanofi made a surprising announcement: Public demand for Beyfortus — the brand name of nirsevimab, the company’s new product aimed at protecting newborns from severe respiratory syncytial virus (RSV) infections — had wildly outpaced supply.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045